Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus autologous stem cell transplantation followed by lenalidomide in relapsed multiple myeloma
2009-013856-61Phase 3Completed
- Sponsor
- Heidelberg University Hospital
- Start
- Dec 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenalidomide, dexamethasone and melphalan in multiple myeloma (MM) (2 arms), sponsored by Heidelberg University Hospital. Primary endpoint: Progression-free survival. Started Dec 2009; status: completed.
02
Drugs
lenalidomidedexamethasonemelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2009-013856-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013856-61.